Harand, Caroline
Daniel, France
Mondou, Audrey
Chevanne, Damien
Creveuil, Christian
Defer, Gilles
Funding for this research was provided by:
Merck Serono
Article History
Received: 10 October 2018
Accepted: 10 September 2019
First Online: 29 October 2019
Ethics approval and consent to participate
: This trial was registered under “Minimal risk and constraint interventional research” in accordance with the terms of article L.1121–1 of the French Public Health Code (act number 2012–300 of March 5, 2012 and its implementing decree number 2016–1537 of November 16, 2016). Ethical approval was granted by the French Regional Ethics Committee (CPP Nord Ouest II; trial reference 2017/53) on September 7, 2017 (ID RCB 20 17-A017 36–47). Informed consent will be obtained for all participants.
: The authors consent to publication of this article.
: The funders had no involvement in the collection, management, analysis, or interpretation of data. GD received personal compensation for serving on scientific advisory boards of Biogen Idec, Novartis, Genzyme, Merck Serono, and Teva and received funding for travel and/or speaker honoraria from Merck Serono, Biogen Idec, Sanofi-Genzyme, Novartis, and Teva. The other authors declare that they have no competing interests.